Zobrazeno 1 - 10
of 72
pro vyhledávání: '"O V, Knyazev"'
Autor:
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. F. Babaian, T. V. Shkurko, B. A. Nanaeva, I. A. Li
Publikováno v:
Медицинский совет, Vol 0, Iss 14, Pp 96-106 (2022)
Introduction. According to clinical guidelines, the treatment of patients with ulcerative colitis (UC) is carried out as combination therapy with mesalazine in rectal forms.The aim was to compare the effectiveness of treatment of moderate severity UC
Externí odkaz:
https://doaj.org/article/f212816e7d5847a8a36a01ebd2d83fa8
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 144-151 (2021)
Introduction. Ulcerative colitis (UC) is one of the severe therapeutic diseases. High doses of oral granular mesalazine are required to maintain clinical and endoscopic remission of UC, which may be sufficient and supposedly more acceptable for patie
Externí odkaz:
https://doaj.org/article/b26de7283f0e4cc4983434bb728035e6
Autor:
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, I. A. Li, D. V. Podolskaya, T. V. Shkurko, B. A. Nanaeva, T. L. Aleksandrov, T. A. Baranova, I. A. Tishaeva, M. Yu. Zvyaglova, A. I. Parfenov
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 20-29 (2021)
Introduction. Tofacitinib is the first member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis (UC). The article presents a three-year Russian experience of tofacitinib use for the treatment of mode
Externí odkaz:
https://doaj.org/article/f0ccd53b02d34cefa5b317533f978e88
Publikováno v:
Медицинский совет, Vol 0, Iss 5, Pp 113-123 (2021)
Introduction. Treatment of patients with ulcerative colitis (UC) requires continuous anti-relapse therapy. Mesalazines are the firstline disease-modifying drugs for the treatment of mild to moderate UC to manage exacerbations and to induce and mainta
Externí odkaz:
https://doaj.org/article/97ea09b3bb8542fa8e0cd6a8e7daad39
Autor:
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 150-157 (2021)
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We incl
Externí odkaz:
https://doaj.org/article/7b2a05de304e4187a8a9f0dd6dd2c75c
Publikováno v:
Терапевтический архив, Vol 92, Iss 2, Pp 104-111 (2020)
Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxy
Externí odkaz:
https://doaj.org/article/7d742ee1631244bba86b71c6445099c9
Publikováno v:
Терапевтический архив, Vol 92, Iss 2, Pp 4-11 (2020)
The article is devoted to the current data regarding the pathogenesis, classification and frequency of extraintestinal manifestations (EIMs) in inflammatory bowel diseases. We discuss two distinct theories of EIMs pathogenesis. First, EIMs arise from
Externí odkaz:
https://doaj.org/article/9aa63d44b92d4ceaacd71f2501601fd8
Autor:
I. V. Gubonina, O. B. Shchukina, N. I. Stuklov, T. V. Gaponova, D. I. Abdulganieva, O. V. Knyazev, N. S. Gubonina
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 47, Iss 8, Pp 721-732 (2020)
Anemia is a frequent systemic complication and extra-intestinal manifestation of inflammatory bowel diseases (IBD). Despite significant progress in IBD treatment, late diagnosis and insufficient correction of concomitant anemia remain a problem in ro
Externí odkaz:
https://doaj.org/article/6655bea97ea24abe9891fb0568cfa0c1
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 47, Iss 6, Pp 568-578 (2019)
Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors and immunological pathways, in particular, genetic polymorphisms of IL-23R, which determines th
Externí odkaz:
https://doaj.org/article/16b04df0081642ce9a86fffe5348c3e4
Publikováno v:
Медицинский совет, Vol 0, Iss 14, Pp 80-86 (2019)
Aim of the study. To compare the efficacy of treatment of patients with moderate left-sided and overall affection ulcerative colitis (UC) receiving equivalent doses of mesalazines – Mesacol and Salofalk.Materials and methods. 90 UC patients of medi
Externí odkaz:
https://doaj.org/article/60c151eb79e54deeb73331aba6bd8948